Loading...
Filament Health Corp.
FH.NE•NEO
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.01
CA$-0.00(-33.33%)

Over the last four quarters, Filament Health Corp. achieved steady financial progress, growing revenue from $1.73M in Q4 2023 to $19021.00 in Q3 2024. Gross profit stayed firm with margins at 100% in Q3 2024 versus 97% in Q4 2023. Operating income totaled $0.00 in Q3 2024, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$914197.00. Net income rose to -$976419.00, with EPS at -$0.004. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan